Trial Profile
A Single-Center Trial Comparing Sunitinib Four-Weeks On/Two-Weeks Off Versus Two-Weeks On/One-Week Off Schedule In Patients With Metastatic Renal Cell Carcinoma.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 Dec 2016
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- 23 Dec 2016 New trial record